Related Experiment Videos
A 5-bromodeoxyuridine-sensitive interval during drosophila myogenesis
Differentiation; Research in Biological Diversity
|March 16, 1976
Summary
5-bromodeoxyuridine (BrdU) inhibits Drosophila myogenesis by incorporating into DNA during the final S phase of myoblast development. Thymidine can prevent this inhibition if administered before the final cell division.
Area of Science:
- Developmental Biology
- Cell Biology
- Molecular Biology
Background:
- Myogenesis, the formation of muscle tissue, is a complex process involving cell differentiation and proliferation.
- Understanding the molecular mechanisms that regulate myogenesis is crucial for developmental biology research.
Purpose of the Study:
- To investigate the effects of 5-bromodeoxyuridine (BrdU) on Drosophila myogenesis in vitro.
- To determine the critical timing of BrdU treatment for inhibiting muscle development.
Main Methods:
- In vitro monitoring of Drosophila myogenesis.
- Treatment of myoblasts with 5-bromodeoxyuridine (BrdU) or thymidine at specific developmental intervals.
- Assessment of cell survival, contractility, and nucleotide uptake.
Main Results:
- The final S phase for Drosophila myoblasts in vitro occurs between 1.3 and 3.3 hours post-gastrulation initiation.
- Treatment with 10(-4) M BrdU during this S phase inhibited myogenesis.
- Thymidine administration before the final myoblast division prevented or reversed BrdU-induced inhibition.
Conclusions:
- BrdU incorporation into DNA during the critical S phase inhibits Drosophila myogenesis.
- The timing of BrdU exposure relative to the final myoblast division is critical for its inhibitory effect.